Literature DB >> 19770289

Is vancomycin ototoxicity a significant risk?

Ryan K Shields, Jay L Martello, Brian A Potoski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19770289      PMCID： PMC2764170          DOI： 10.1128/AAC.00537-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  11 in total

1.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2005-02-15       Impact factor: 21.405

Review 2.  The pharmacokinetic and pharmacodynamic properties of vancomycin.

Authors:  Michael J Rybak
Journal:  Clin Infect Dis       Date:  2006-01-01       Impact factor: 9.079

Review 3.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

4.  High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.

Authors:  Levita K Hidayat; Donald I Hsu; Ryan Quist; Kimberly A Shriner; Annie Wong-Beringer
Journal:  Arch Intern Med       Date:  2006-10-23

5.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 6.  Audiologic monitoring for ototoxicity.

Authors:  K C Campbell; J Durrant
Journal:  Otolaryngol Clin North Am       Date:  1993-10       Impact factor: 3.346

7.  Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice.

Authors:  L S Elting; E B Rubenstein; D Kurtin; K V Rolston; J Fangtang; C G Martin; I I Raad; E E Whimbey; E Manzullo; G P Bodey
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

8.  Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity.

Authors:  Thomas P Lodise; Ben Lomaestro; Jeffrey Graves; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

9.  Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.

Authors:  Gregory Steinkraus; Roger White; Lawrence Friedrich
Journal:  J Antimicrob Chemother       Date:  2007-07-10       Impact factor: 5.790

10.  A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia.

Authors:  Meghan N Jeffres; Warren Isakow; Joshua A Doherty; Scott T Micek; Marin H Kollef
Journal:  Clin Ther       Date:  2007-06       Impact factor: 3.393
View more
  2 in total

Review 1.  How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?

Authors:  Gloria Wong; Fekade Bruck Sime; Jeffrey Lipman; Jason A Roberts
Journal:  BMC Infect Dis       Date:  2014-11-28       Impact factor: 3.090

2.  Long-term vancomycin use had low risk of ototoxicity.

Authors:  Clayton Humphrey; Michael P Veve; Brian Walker; Mahmoud A Shorman
Journal:  PLoS One       Date:  2019-11-06       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.